INHALE-3 is a Phase 4, randomized controlled trial (RCT) that will randomly assign participants ≥18 years of age with type 1 diabetes (T1D) using multiple daily injections (MDI), an automated insulin delivery (AID) system, or a pump without automation, and continuous glucose monitoring (CGM) 1:1 to an insulin regimen of insulin degludec plus inhaled insulin (Afrezza) and CGM or continuation of usual care. The primary outcome of the RCT is at 17 weeks. The RCT will be followed by a 13-week extension phase in which participants in both groups will use the degludec-inhaled insulin regimen.
Conditions
- Diabetes Mellitus, Type 1
Intervention
- Afrezza
- insulin degludec
- Rapid-acting Insulin Analog
- Basal Insulin
Principal Investigator
- Codorniz, Kevin
Sponsor
- MannKind
*The source of data for this particular study is "ClinicalTrials.gov" and was last updated on 05/16/2024. Loma Linda University does not make any warranties, expressed or implied, with respect to such data, and, furthermore, assumes no liability for any party's use, or the results of such use of the data.
Request Information
Complete the form below to contact the study team and receive more information about this trial.